Natco Pharma to acquire Dash Pharma
Hyderabad: Drug maker, Natco pharma, has recently announced that the company through its affiliates is proposing to enter into an agreement to acquire 100 percent stake in Dash Pharmaceuticals LLC.
The acquisition is subjected to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements. This acquisition provides NATCO with a front-end to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.
"The indicative time period for completion of the acquisition is January 31, 2022," the company informed in a BSE filing.
The company further informed that the nature of consideration for the deal is US$ 18 million in cash.
Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, USA which is expected to have approximate net sales of USD 15 million for the year ending December 2021.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.